Log In
Print
BCIQ
Print
Print this Print this
 

Anti-IL13, lebrikizumab (MILR1444A, RG3637) (formerly TNX-650)

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionHumanized mAb targeting IL-13
Molecular Target Interleukin-13 (IL-13)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAsthma
Indication DetailsTreat asthma; Treat asthma in adolescents inadequately controlled with inhaled corticosteroids; Treat asthma in adults inadequately controlled with inhaled corticosteroids; Treat severe uncontrolled asthma
Regulatory Designation

Partner

Chugai Pharmaceutical Co. Ltd.; Roche


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today